Topline results were announced from a phase 3 trial evaluating bictegravir 75mg/lenacapavir 50mg (BIC/LEN), an investigational single-tablet regimen for the treatment of HIV-1.
Janssen announced positive topline results from a Phase 3 trial for an investigational long-acting 2-drug regimen for HIV-1 infection. The ATLAS study enrolled 570 patients infected with HIV-1; ...
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback